Lower Saxony promotes its biotech credentials
This article was originally published in Clinica
The German federal state of Lower Saxony is a success story for biotechnology companies in Germany, says Lower Saxony president Sigmar Gabriel. Speaking last week at the 4th biotechnology conference of the federal ministry of education and research (BMBF) in Braunschweig, Mr Gabriel said that the German lower house's (Bundestag's) decision to allow stem cell research (see Clinica No 1006, p 5) was a step in the right direction, but that the country needed to go further still. "It is no longer a question of whether we decide to use this 'cross-sectional' technology, but how we become a worldwide competitor in this field," he said.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.